About Influenza B Virus Hemagglutinin (HA) Recombinant Protein (B/Tokyo/EIS13-175/2025, Victoria Lineage)

Influenza B virus is an enveloped, negative-sense segmented RNA virus belonging to the family Orthomyxoviridae. Hemagglutinin (HA) is the major viral surface glycoprotein responsible for viral attachment to sialic acid-containing receptors on host cells and initiation of membrane fusion during viral entry. As the principal surface antigen, HA is the primary target of neutralizing antibodies and seasonal influenza vaccines. The B/Tokyo/EIS13-175/2025 strain belongs to the B/Victoria lineage and was selected by the World Health Organization (WHO) as the influenza B vaccine component for the 2026–2027 Northern Hemisphere influenza season, making it an important reagent for influenza surveillance and vaccine research.

eEnzyme's Influenza B Virus Hemagglutinin (HA) Recombinant Protein (B/Tokyo/EIS13-175/2025) is produced for research use and is suitable for antibody screening, receptor-binding studies, ELISA development, Western blotting, epitope mapping, structural characterization, and influenza vaccine research. This recombinant protein provides a valuable reagent for investigating influenza B virus biology, host immune responses, and antiviral therapeutic development.

Applications

Biological Significance of Influenza B Hemagglutinin

Influenza B HA is the functional viral attachment and fusion protein that initiates infection by recognizing sialic acid receptors on susceptible host cells. As the dominant antigen recognized by protective antibodies, HA remains the primary target for seasonal influenza vaccines and therapeutic antibody development. The Influenza B Virus Hemagglutinin (HA) Recombinant Protein (B/Tokyo/EIS13-175/2025) provides a valuable research tool for studies of influenza virus pathogenesis, immune responses, vaccine evaluation, and diagnostic assay development.